News: Simtuzumab

We provide the latest news and info on Simtuzumab


Bidness Etc
Intercept Could Soon Be The Market Leader For Obesity Treatment
Bidness Etc
Gilead's monoclonal antibody, Simtuzumab, has reached the second phase of trials, while Novo Nordisk's weight loss medication, Victoza, is awaiting FDA approval. A big advantage for Intercept will be the high pricing it can assign to its first-in-class ...

and more »

Published on Monday 1st of September 2014 08:34:10 AM Read more...

2 Healthcare Stocks That Appear To Trade Below Fair Value Estimates
Seeking Alpha (registration)
... years with patent expirations and increased competition in the burgeoning HCV marketplace, Gilead's extensive pipeline into HIV, liver diseases, and orphan conditions like idiopathic pulmonary fibrosis (e.g., simtuzumab, a LOXL2 inhibitor that ...

Published on Monday 1st of September 2014 08:34:10 AM Read more...

Gilead Is Going To Make More Money In The Future
Seeking Alpha (registration)
In addition to the ph3 trials for GS-5816 pan-GT HCV regimens and 4-6 week readouts, we think the potential impact of simtuzumab ("S-Mab") and TAF is underappreciated at the current multiple (9.3x our new 2015 EPS). We specifically look for signals in ...

and more »

Published on Monday 1st of September 2014 08:34:10 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts